Corcept Therapeutics (CORT) Misses Q4 EPS by 12c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $83.03 +3.19%
Revenue Growth %: +56.0%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
INM, TRI, CRVL, More
Revenue Growth %: +56.0%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.26, $0.12 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $181.89 million versus the consensus estimate of $198.05 million.
GUIDANCE:
Corcept Therapeutics sees FY2025 revenue of $900-950 million, versus the consensus of $855.1 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top E-Commerce Stock Pick from BMO Capital Markets
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Sportradar Group AG (SRAD) Reports In-Line Q3 EPS ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
